CB
NBIX icon

Commerce Bank’s Neurocrine Biosciences NBIX Stock Holding History

Commerce Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Sell
13,249
-43
-0.3% -$6.38K 0.01% 538
2026
Q1 		$1.75M Buy
13,292
+11,680
+725% +$1.55M 0.01% 575
2025
Q4 		$229K Buy
1,612
+32
+2% +$4.64K ﹤0.01% 1164
2025
Q3 		$222K Buy
+1,580
New +$214K ﹤0.01% 1166
2024
Q4 		– Sell
-4,199
Closed -$484K – 1215
2024
Q3 		$484K Buy
4,199
+108
+3% +$14.8K ﹤0.01% 896
2024
Q2 		$563K Buy
+4,091
New +$561K ﹤0.01% 808
2022
Q2 		– Sell
-2,166
Closed -$203K – 1181
2022
Q1 		$203K Buy
+2,166
New +$184K ﹤0.01% 1134
2021
Q3 		– Sell
-6,176
Closed -$601K – 1175
2021
Q2 		$601K Sell
6,176
-12
-0.2% -$1.15K ﹤0.01% 766
2021
Q1 		$602K Buy
6,188
+280
+5% +$29.4K ﹤0.01% 749
2020
Q4 		$567K Buy
5,908
+2,065
+54% +$199K ﹤0.01% 726
2020
Q3 		$370K Buy
3,843
+63
+2% +$7.29K ﹤0.01% 788
2020
Q2 		$461K Sell
3,780
-12
-0.3% -$1.33K ﹤0.01% 694
2020
Q1 		$328K Buy
3,792
+1,177
+45% +$115K ﹤0.01% 731
2019
Q4 		$281K Buy
+2,615
New +$274K ﹤0.01% 847

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Commerce Bank's NBIX Position: Q2 2026 in Review

Commerce Bank reduced its Neurocrine Biosciences (NBIX) stake by 0.32% in Q2 2026, selling an estimated $6.38K and leaving 13,249 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #538.

Commerce Bank first reported a position in NBIX in Q4 2019 and has held it in 14 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Commerce Bank held 13,249 shares of Neurocrine Biosciences worth $2.23M as of Q2 2026.
  • Commerce Bank sold 43 Neurocrine Biosciences shares in Q2 2026, an estimated $6.38K.
  • Neurocrine Biosciences made up 0.01% of Commerce Bank's portfolio in Q2 2026, its #538 holding.
  • Commerce Bank first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 14 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Commerce Bank's 13F filing for Q2 2026, filed 12 Aug 2026.